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White matter hyperintensities (WMH) are an important predictor of both stroke and cognitive impairment.1 
Their prevalence increases markedly with age,1 and hyper-
tension is an important independent risk factor.2,3 Both the 
duration of hypertension and its severity predict the presence 
and extent of WMH.2,3 They are believed to represent cerebral 
small vessel disease (SVD), although their pathogenesis is 
incompletely understood. Twin and family studies quantifying 
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WMH on MRI suggest that the heritability (proportion of dis-
ease risk explained by genetic predisposition) is as high as 
55% to 80%.4–7 Despite this, genome-wide association stud-
ies (GWAS) have only identified 1 common variant increasing 
WMH risk at chromosome 17q25.8,9
This inability of GWAS to identify the variants accounting 
for the expected genetic risk, or missing heritability, has been 
reported in other complex genetic diseases in which the cumu-
lative risk explained by common variants identified by GWAS 
is considerably less than that predicted by the heritability found 
in epidemiological studies.10 Several proposals have been sug-
gested to account for these discrepancies, including a role for 
rare variants that are not easily detectable with GWAS arrays, 
as well as gene–environment interactions, and epistasis.10
Another confounding factor is potential heterogeneity of the 
phenotype. If it is not accounted for in GWAS experiments, 
it could markedly reduce the power to detect genetic associa-
tions. This may be particularly relevant for WMH in which 
neuropathological studies have suggested heterogeneous dis-
ease processes.11,12 It has been suggested that smaller punctate 
lesions may represent a nonischemic cause, whereas larger 
confluent lesions are more likely to be due to SVD pathology.13
Hypertension is a well-established risk factor for WMH,2,3 
and in hypertensive individuals, WMH pathology may differ 
from that in nonhypertensive individuals, possibly with a greater 
extent of ischemic SVD.14 Therefore, WMH genetic architec-
ture might also differ across patient subgroups defined on the 
basis of vascular risk factors. We hypothesized that WMH heri-
tability estimates would increase if the study cohort was divided 
on the basis of presence or absence of WMH-associated risk 
factors because of individual subgroups having reduced hetero-
geneity. GWAS data from unrelated individuals can be used to 
obtain an estimate of heritability.15 Using genome-wide com-
plex trait analysis (GCTA), the proportion of phenotypic vari-
ance explained by single nucleotide polymorphisms (SNPs) on 
conventional genotyping arrays can be determined.
To examine these associations, we used GWAS data from 
2366 subjects with ischemic stroke in whom the WMH volume 
(WMHV) was quantified. These individuals have more severe 
WMH than do age-matched population individuals,1 and this 
may, therefore, increase power when examining genetic asso-
ciations with WMHV. We first performed multivariate regres-
sion to determine the most important risk factors in our data. 
We then used GCTA to estimate the heritability of WMH in 




Patients with ischemic stroke enrolled through 7 hospital-based 
studies and 1 population-based cohort underwent genome-wide ge-
notyping and volumetric WMH analysis, as previously described9 
(Methods in the online-only Data Supplement). All subjects were 
adults (>18 years) of self-reported European ancestry, and had a di-
agnosis of ischemic stroke of any subtype. Exclusion criteria were 
cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy, vasculitis, demyelinating, and mitochon-
drial disorders. Cohort demographics and clinical characteristics are 
shown in Table 1. Cases were subtyped based on clinical features, 
brain imaging, and ancillary investigation findings using the Trial 
of Org 10172 in Acute Stroke Treatment (TOAST) classification.16 
Subtyping was performed at individual recruitment centers by an ex-
perienced stroke physician or neurologist.
Risk Factor Definitions
Hypertension was defined as prescription of antihypertensives before 
stroke or systolic blood pressure >140 mm Hg or diastolic blood pres-
sure >90 mm Hg >1 week post stroke. Hypercholesterolemia was de-
fined as treatment with lipid-lowering agents before stroke or elevated 
serum cholesterol (>5.2 mmol/L) on stroke admission. Ever-smoker 
was defined as current and ex-smokers. Type 2 diabetes mellitus was 
defined as a previous diagnosis. Ischemic heart disease was defined as 
known diagnosis of coronary artery disease or self-reported history of 
angina, myocardial infarction, coronary bypass surgery, or percutane-
ous coronary intervention.
Neuroimaging Analysis
MRI scans were acquired using different scanners at individual 
centers as part of routine clinical practice for evaluation of stroke. 
Table 1. Cohort Demographics and Clinical Characteristics
WTCCC2-UK WTCCC2-D Milan MGH ASGC ISGS SWISS Total
Age, y (SD) 69.3 (13.7) 66.6 (12.3) 57.5 (14.3) 66.3 (14.6) 65.5 (13.3) 68.4 (14.3) 67.0 (10.4) 66.3 (13.8)
Men (%) 313 (60.5) 425 (62.0) 92 (60.5) 333 (59.9) 59 (56.7) 129 (62.0) 55 (48.7) 1406 (60.2)
Hypertension (%) 364 (70.4) 486 (70.8) 86 (56.6) 356 (64.0) 80 (76.9) 126/207 (60.9) 83 (73.5) 1581/2335 (67.7)
Diabetes mellitus (%) 93 (18.0) 153 (22.3) 20 (13.2) 113 (20.3) 18 (17.3) 8/25 (32.0) N/A 405/2040 (19.9)
High cholesterol 297/449 (66.1) 317 (46.4) 93 (61.2) 226 (40.6) 52 (50.0) 49/127 (38.6) N/A 1034/2074 (49.9)
Ever-smoker 332/514 (64.6) 240 (35.0) 63 (41.4) 284/449 (63.3) 26/99 (26.3) 50/207 (24.2) N/A 995/2207 (45.1)
IHD (%) 99/516 (19.2) 109 (15.9) 20 (13.2) 114 (20.5) 38 (36.5) 50/207 (24.2) N/A 430/2221 (19.4)
SVD stroke (%) 117 (22.6) 57 (8.3) 9 (5.9) 67 (12.1) 5 (4.8) 27 (13.0) N/A 282/2223 (12.7)
LAA stroke (%) 103 (19.9) 215 (31.3) 34 (22.4) 128 (23.0) 22 (21.2) 39 (18.8) N/A 541/2223 (24.3)
CE stroke (%) 79 (15.3) 169 (24.6) 29 (19.1) 224 (40.3) 50 (48.1) 57 (27.4) N/A 608/2223 (27.4)
Unknown (%) 218 (42.2) 245 (35.7) 80 (52.6) 204 (36.7) 27 (30.0) 85 (40.9) N/A 859/2223 (38.6)
Total 517 686 152 556 104 208 113 2336
ASGC indicates Australian Stroke Genetics Collaborative; CE, cardioembolic; D, Germany; IHD, ischemic heart disease; ISGS, Ischemic Stroke Genetics Study; 
LAA, large artery atherosclerosis; MGH, Massachusetts General Hospital; N/A, not applicable; SVD, small vessel disease; SWISS, Siblings With Ischemic Stroke 
Study; UK, United Kingdom; and WTCCC2, Wellcome Trust Case Control Consortium-2.
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WMHV was measured in the hemisphere contralateral to acute in-
farction to avoid confounding by T2 hyperintense signals because of 
acute stroke. Trained raters blinded to all patient information ana-
lyzed anonymized MRI scans. All supratentorial white matter and 
deep gray matter lesions were included, with the exception of WMH 
corresponding to lacunar infarcts. Each center excluded between 5 
and 12.5% of MRI scans because excessive movement of artifact, 
incomplete brain coverage, or bihemispheric infarcts (other than la-
cunar) precluded accurate WMH quantification.
To account for normal interindividual variability in head size, an 
estimate of total intracranial volume (TICV) was derived, using site-
specific volumetric methodology.
MRI scans from the Massachusetts General Hospital, Ischemic 
Stroke Genetics Study (ISGS), and Australian Stroke Genetics 
Collaborative (ASGC) studies were analyzed in Boston. Siblings 
With Ischemic Stroke Study (SWISS) scans were analyzed in the 
same way at the University of Virginia by the Boston-trained rater. 
Fluid-attenuated inversion recovery sequences were analyzed us-
ing an MRIcro (http://www.mricro.com), a semiautomated method 
described previously.17 Using operator-mediated quality assurances, 
overlapping regions of interest corresponding to WMH produced the 
final maps for WMHV calculation. Intracranial area was derived as a 
validated marker of TICV as the average of 2 midsagittal slices traced 
using anatomic landmarks on T1 sequences.18
The Wellcome Trust Case Control Consortium-2 (WTCCC2) and 
Milan cohorts were analyzed in London using DISPunc semiautomated 
lesion drawing software.19 WTCCC2 consisted of cases recruited from 
the following centers: Munich, St. George’s, Oxford, and Edinburgh. 
For WMH quantification, fluid-attenuated inversion recovery was pri-
marily used, and in its absence, T2 was used. A seed at the lesion border 
was first manually marked and then outlined automatically based on 
the signal intensity gradient. Regions of interest were manually cor-
rected as required. For TICV, T2 was primarily used, and in its absence, 
fluid-attenuated inversion recovery sequences. Images were segmented 
using an automated program, SIENAX,20 and TICV was derived by 
summing cerebrospinal fluid, gray and white matter volumes.
WMH quantification agreement across the 2 main reading centers 
was performed for 50 randomly selected scans; agreement was good 
(intraclass correlation coefficient, 0.95; confidence interval, 0.91–0.97).
Genotype Analysis
All genotyping was performed using the Illumina Human660W-
Quad, 650K-Quad, or 610-Quad beadchips with the exception of 
Massachusetts General Hospital samples genotyped on the Affymetrix 
6.0 Beadchip. Standardized quality control procedures were applied 
before imputation using IMPUTE version 2 (http://mathgen.stats.
ox.ac.uk/impute/impute_v2.html) and HapMap3 and 1000 Genomes 
Project Phase pilot (June 2010). Imputed genotype dosage data were 
converted to hard-call using a strict level of confidence (r2>0.95) in 
PLINK version 1.07 (http://pngu.mgh.harvard.edu/≈purcell/plink/). 
Per-center strict quality control procedures were then applied; SNPs 
that were either rare (minor allele frequency, <0.01) or missing in 
>1% of genotypes were discarded. After quality control, there were 
472,591 consensus autosomal SNPs from the merged genotyped data 
remaining for heritability analysis.
Statistical Analyses
For statistical analyses, SPPS version 16 (http://www.ibm.com/soft-
ware/uk/analytics/spss) and R version 3.1.1 (http://www.r-project.
com) were used, and P<0.05 was considered significant. To minimize 
WMHV measurement biases secondary to differing imaging param-
eters, MRI scans from individual centers were analyzed separately 
and divided into groups based on the availability of fluid-attenu-
ated inversion recovery or T2 for WMH quantification (Table I in 
the online-only Data Supplement). Single-hemisphere WMHV was 
doubled to obtain whole-brain values and log-transformed. WMHV 
was adjusted for age and TICV by deriving standardized residuals 
from a linear regression model, including these as predictors. For 
SWISS samples only, WMHV was adjusted for intracranial volume 
before transformation by multiplying by the ratio of mean intracra-
nial area:individual intracranial area. The age- and TICV-adjusted 
WMHV residuals formed the phenotype for risk factor predictor and 
heritability analyses.
Predictors of WMHV
Univariate regression was used to assess the relationship of binary 
cardiovascular risk factors (hypertension, diabetes mellitus, ever-
smoker, sex, ischemic heart disease, and hypercholesterolemia) with 
adjusted WMHV. Subjects with missing risk factors or subtype in-
formation were excluded from individual analyses. Stroke subtypes 
were also assessed as predictors of adjusted WMHV. Subjects with no 
determined stroke cause or >1 potential stroke cause were excluded 
from these analyses. All significant risk factors were included in a 
multivariate linear regression, predicting adjusted WMHV, and those 
with persistent significance were used to stratify the data for heritabil-
ity analyses.
Heritability Analyses
To estimate the heritability from the GWAS data, we used the ge-
nome-wide Complex Tool version 1.02 (http://www.complextrait-
genomics.com/software/gcta/).15,21 This estimates the phenotypic 
variance attributable to common SNPs, referred to here as SNP heri-
tability (HSNP). Statistically significant HSNP was defined as P<0.05 for 
all likelihood ratio tests applied to the analyses. First, a genetic rela-
tionship matrix was derived on a per-chromosome basis and merged 
into a single autosomal matrix and adjusted for prediction errors due 
to imperfect linkage disequilibrium. One of a pair of individuals with 
estimated relatedness ≥0.125 was removed, corresponding to third-
degree relatives. Ancestry informative principal components were 
derived within GCTA.
We first calculated the HSNP of WMHV adjusted for age and TICV 
in the entire cohort, using a restricted maximum likelihood, cova-
rying for 10 ancestry principal components. To determine the effect 
of controlling for clinically important covariates, we performed a 
second analysis in which sex and hypertension status were added as 
covariates.
To test the hypothesis that WMH heritability increases in risk 
factor–defined groups, we derived HSNP in subjects subgrouped on 
the basis of presence or absence of significant predictors of WMHV. 
In these stratified analyses, WMHV was adjusted only for age and 
TICV. We needed to determine whether increases in HSNP in the pres-
ence of risk factors were significantly more than expected by chance. 
One thousand permutations were performed in which subsets of in-
dividuals were selected randomly at rates reflecting the risk factor 
prevalence in individual centers (Table 1). HSNP was calculated in 
these subsets, and P values reflected the proportion of permutations 
in which HSNP was greater or equal to the observed HSNP within risk 
factor–defined groups.
We also applied bivariate linear mixed modeling within GCTA22 
to calculate the genetic correlation of WMHV, in the presence and 
absence of significant risk factors, as tagged by genome-wide SNPs. 
In this setting, genetic correlation reflects the extent to which ge-
netic susceptibility is shared between risk factor–defined subgroups. 
Finally, genotype–environment interactions were investigated using 
a model that included the main effects of the environmental factor 
as fixed effects and the genotype–environment interaction effect as 




In univariate analyses, female sex, hypertension, diabetes mel-
litus, and SVD stroke subtype were significant predictors of 
WMHV (Table II in the online-only Data Supplement). After 
multivariate linear regression, female sex (B=0.097; SE=0.061; 
P=0.021), hypertension status (B=0.138; SE=0.045; P=0.02), 
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and SVD stroke subtype status (B=0.430; SE=0.061; P<0.001) 
independently predicted WMHV (Table III in the online-only 
Data Supplement), and they were, therefore, taken forward to 
stratified heritability analyses. The small number of SVD sub-
type individuals, however, precluded SVD stratified heritabil-
ity analyses using GCTA.
Heritability Analyses
We estimated that a significant proportion of age- and TICV-
adjusted WMHV variance was attributable to common SNPs 
(HSNP=0.21; SE=0.09; P=0.0065; Table 2). HSNP estimates for 
WMHV remained stable after additional adjustment for sex 
and hypertension status (HSNP=0.23; SE=0.09; P=0.0026).
HSNP estimates were higher among hypertensive individu-
als (HSNP=0.45; SE=0.12; P=7.99×10−5), and this increase was 
greater than that expected by chance (P=0.012 from permuta-
tion). In contrast, estimates were lower and nonsignificant in 
nonhypertensive individuals (HSNP=0.13; SE=0.25; P=0.13). 
HSNP was also higher among women (0.40 versus 0.18 in men), 
but this was not greater than that expected by chance (P=0.164 
from permutation).
We estimated the degree of genetic correlation of WMHV 
in the presence and absence of significant risk factors. We 
identified a significant genetic correlation between men and 
women (r2=0.83; P=0.04). Conversely, we found no signifi-
cant genetic correlation in WMHV between hypertensive and 
nonhypertensive individuals (r2=0.15; P=0.40). These results 
indicate that SNPs predicting WMHV are shared between 
men and women, but they differ for hypertensives and nonhy-
pertensives. This was also supported by interaction analyses, 
which revealed significant gene–environment interaction with 
hypertension status (Vg×e =0.33; SE=0.17; P=0.017) but not 
with sex (P=0.50; Table 3), indicating that genetic risk factors 
interact with hypertension status to increase WMHV.
Discussion
Using GWAS data from ischemic stroke cohorts, we found 
that a significant proportion of variance in WMHV is attribut-
able to common SNPs on genome-wide arrays with an herita-
bility estimate of 21% to 23%. In comparison, using similar 
heritability methods has given HSNP estimates of 38% in isch-
emic stroke,23 24% in Alzheimer disease, and 30% in multiple 
sclerosis.24 Our WMHV heritability estimates are consider-
ably lower than those from twin and family studies, which 
range between 55% and 80%.4–7 Our results suggest that a 
major reason for the lower heritability estimates from GCTA 
may be heterogeneity in the WMH phenotype, with differ-
ent genetic architecture in hypertensive and nonhypertensive 
individuals.
Apart from age, hypertension is the most important conven-
tional risk factor for WMH.2,3 We found significantly greater 
heritability estimates of 45% in the hypertensive group com-
pared with 13% in nonhypertensive individuals. We found that 
a significant proportion of WMHV phenotypic variance was 
attributable to a hypertension–gene interaction. This indicates 
that different genetic variations contribute to WMHV in the 
presence and absence of hypertension. In contrast, the high 
genetic correlation between sexes (r2=0.83) without evidence 
of an interaction by sex indicates shared WMH causes in men 
and women, as would be expected. Therefore, the HSNP dif-
ference across sexes is likely driven by nongenetic factors, 
and our finding that female sex is a predictor of WMH could 
reflect sex differences in physiological, immune, or behavioral 
risk factors25 not accounted for in these analyses.
Estimates of heritability derived from genome-wide data are 
often lower when compared with those derived from pedigree-
based studies,15,24 and there are many reasons for this. Unlike 
genome-wide data, pedigree-based heritability estimates cap-
ture the variance not only from common variants but also from 
rare, structural, and poorly tagged variants.15 They are also 
susceptible to overestimation because of shared family envi-
ronments.10 Our data demonstrate that phenotypic heterogene-
ity could also contribute to this discrepancy because traits are 
likely to be less varied in pathogenesis within families than in 
unrelated individuals. This is particularly relevant to WMH, a 
radiological marker of various pathophysiological processes. 
Consistent with this, the HSNP for WMHV is high in cerebral 
autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy (HSNP=0.85), a monogenic disease 
characterized by confluent WMH secondary to a small-vessel 
arteriopathy.26
Our results support the hypothesis of reduced WMH het-
erogeneity among risk factor–defined subgroups and also sug-
gest that different pathophysiological mechanisms contribute 
to disease in hypertensives and nonhypertensives, consistent 
with pathological data.13,14
There are several limitations in this study. First, we use 
genome-wide data from several cohorts genotyped using vari-
ous platforms. To minimize propagating genotyping bias, we 
applied strict levels of imputation confidence and genotyping 
call rates to derive a consensus set of SNPs. As a result of limited 
Table 2. HSNP for WMHV for All Cases and Stratified by 
Significant Risk Factors and Genomic Inflation Factor (λ) for 
WMHV Genome–Wide Association Analyses
Risk Factor Strata n H
SNP
 (SE) P Value λ
All cases 2243 0.21 (0.09) 0.0065* 1.02
Sex Female 889 0.40 (0.20) 0.020* 1.04
Male 1353 0.18 (0.14) 0.092 1.01
Hypertension Hypertensives 1515 0.45 (0.12) 7.99×10−5* 1.05
Nonhypertensives 727 0.13 (0.25) 0.31 1.00
H
SNP
 indicates SNP heritability; SNP, single nucleotide polymorphism; and 
WMHV, white matter hyperintensity volume.
*P<0.05.
Table 3. Genetic Correlation of WMHV Across Risk  
Factor–Stratified Groups and Phenotypic Variance Attributable 












Sex 0.83 (0.57) 0.04* <0.01 (0.12) 0.21 (0.12) 0.50
Hypertension 0.15 (0.56) 0.40 0.33 (0.17) 0.04 (0.13) 0.017*
Standard errors (SE) shown in brackets. WMHV indicates white matter 
hyperintensity volume.
*P<0.05.
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coverage, heritability estimates are likely to be conservative. 
Second, our cohorts were drawn from several international 
studies, giving the potential for population stratification; how-
ever, we show that all samples used are European in ancestry. 
Furthermore, there are differences in risk factor rates (Table 1) 
among cohorts, raising the possibility of systematic diagnostic 
biases underlying differences in risk factor–stratified heritabil-
ity estimates. However, WMHV genome–wide analyses did 
not reveal significant inflation of test statistics (λ≤1.05) overall 
or within risk factor–stratified groups (for QQ plots).
In summary, our results suggest that different genetic influ-
ences may operate in WMH in hypertensive individuals com-
pared with those found in nonhypertensive individuals. Our 
results suggest that future GWAS studies in WMH may gain 
power by stratifying by hypertension status or by including 
a gene–hypertension interaction term in association models. 
Furthermore, these data may prove relevant to the future stud-
ies of other complex phenotypes.
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1) SUPPLEMENTAL TABLES  
 
Table I. Means and standard deviations (SD) of White Matter Hyperintensity Volume (WMHV) and 
Intracranial Volume (TICV) or Area (ICA) in different study centers divided on the basis magnetic 
resonance imaging (MRI) T2 or fluid-attenuated inversion recovery (FLAIR) sequence availability.   
 
Cohorts Groups WMHV (cm3) TICV (cm3) or ICA 
(cm2)  
WTCCC-UK St George’s 9.15 (SD 12.29) 1621.3 cm3 (SD 165.9) 
 Oxford (FLAIR) 4.54 (SD 6.08) 1581.9 cm3 (SD 164.5) 
 Oxford (T2) 3.09 (SD 5.15) 1585.3 cm3 (SD 138.5) 
 Edinburgh 5.93 (SD 8.18) 1463.3 cm3 (SD 148.8) 
WTCCC-D Munich (FLAIR) 3.53 (SD 5.86) 1530.6 cm3 (SD 136.4) 
 Munich (T2) 3.41 (SD 6.77) 1592.7 cm3 (SD 152.4) 
Milan - 3.42 (SD 8.49) 1571.7 cm3 (SD 140.9) 
MGH - 13.1 (SD 14.8) 153.2 cm2 (SD 13.6) 
ASGC - 8.35 (SD 9.87) 154.2 cm2 (SD 9.2) 
ISGC - 8.73 (SD 11.3) 153.8 cm2 (SD 13.6) 
SWISS - 8.30 (SD11.7)* N/A 
FLAIR= Fluid Attenuated Inversion Recovery, SWISS= Siblings With Ischemic Stroke Study, 
ASGC= Australian Stroke Genetics Collaboration, ISGC=Ischemic Stroke Genetics Consortium, 
MGH=Massachusetts General Hospital. *adjusted WMHV=WMHV×(mean ICA/individual ICA) 
 
Table II. Results of univariate linear regression test statistics for cardiovascular risk factor and stroke 
subtype predictors of age-adjusted WMHV. *p<0.05 
 
 N Effect Size (SE) P-value 
Male Gender 2336 -0.088 (0.040) 0.027* 
Hypertension 2223 0.152(0.041) <0.001* 
Diabetes 2040 0.115(0.052) 0.027* 
Ever-smoker 2207 0.000(0.001) 0.579 
Cholesterol 2074 -0.016(0.041) 0.690 
IHD 2221 0.000(0.001) 0.688 
LAA subtype 2223 -0.020(0.046) 0.664 
CE subtype 2223 -0.020(0.044) 0.153 
SVD subtype 2223 0.439(0.059) <0.001* 
IHD= Ischemic Heart Disease, LAA= Large Artery Atherosclerosis, CE= Cardioembolic,  
SVD= Small Vessel Disease.  
 
Table III.  Results of multivariate linear regression test statistics for prediction of age-adjusted 
WMHV. *p<0.05 
 
 Effect Size (SE) P-value 
Male Gender -0.097 (0.061) 0.021* 
Hypertension 0.138(0.045) 0.002* 
Diabetes 0.072(0.052) 0.172 




Table IV. Showing the heritability (HSNP) or variance of WMHV attributable to single nucleotide 
polymorphisms (SNP) partitioned by chromosome. Significant HSNP was defined as *p<0.05 for 
likelihood ratio tests. 
 
 
Chromosome SNP number % SNPs HSNP SE p 
1 41355 8.75 0.008 0.022 0.348 
2 39697 8.40 <0.001 0.025 0.5 
3 35781 7.57 0.041 0.024 0.034 
4 37385 7.91 0.012 0.023 0.30 
5 31900 6.75 0.028 0.024 0.12 
6 36744 7.78 0.046 0.026 0.029* 
7 25653 5.43 <0.001 0.021 0.5 
8 26550 5.62 0.016 0.021 0.227 
9 19814 4.19 <0.001 0.019 0.5 
10 26541 5.62 0.010 0.020 0.299 
11 26385 5.58 0.036 0.022 0.037* 
12 23930 5.06 0.042 0.022 0.014* 
13 18841 3.99 <0.001 0.017 0.5 
14 14267 3.02 0.030 0.020 0.044* 
15 11064 2.34 <0.001 0.015 0.50 
16 8922 1.89 0.002 0.013 0.43 
17 9125 1.93 0.032 0.018 0.014* 
18 14400 3.05 0.009 0.015 0.23 
19 4587 0.97 <0.001 0.010 0.5 
20 10096 2.14 <0.001 0.015 0.5 
21 5215 1.10 <0.001 0.010 0.48 
22 4339 0.92 <0.001 0.011 0.5 




2) SUPPLEMENTAL FIGURES 
 
Figure I. Principle component analysis (PCA) Plots showing first two eigenvectors for three HapMap 
populations and the following ischemic stroke cohorts: (A) WTCCC-UK (B) WTCCC-D (C) Milan 
(D) Australia (E) MGH (F) ISGS (G) SWISS. Yellow=Ischemic stroke, Green=CEU, Red= Yoruba, 
Blue=Chinese and Japanese. 
A	   	   	   	   	   	   	   B	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Figure II. Q-Q plots for genome-wide association analysis for white matter hyperintensity volume in 
(A) entire sample (B) Females (C) Hypertensives (D) Non Small Vessel Disease Subtype. lambda 
</=1.05 for all. 
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Figure IV. Showing SNP Heritability and standard error of WMHV in all cases and risk factor 
defined subgroups. Also showing empirically derived p-values determining whether SNP heritability 
significantly differed across risk factor defined groups. 
 
 





Australian Stroke Genetics Collaborative (ASGC): Stroke cases comprised European-ancestry 
patients admitted to four clinical centers across Australia (The Neurosciences Department at Gosford 
Hospital, Gosford, New South Wales (NSW); the Neurology Department at John Hunter Hospital, 
Newcastle, NSW; The Queen Elizabeth Hospital, Adelaide ; and the Royal Perth Hospital, Perth) 
between 2003 and 2008. Stroke was defined by WHO criteria as a sudden focal neurologic deficit of 
vascular origin, lasting more than 24 hours and confirmed by brain imaging. Other investigative tests 
such as electrocardiogram, carotid Doppler and trans-esophageal echocardiogram were conducted to 
define stroke etiology as clinically appropriate.  
Siblings With Ischemic Stroke Study (SWISS): This is a prospective, multicenter study of sibling 
pairs with first-ever or recurrent ischemic stroke.1 Probands were recruited from 70 clinical centers 
across the US and Canada. Ischemic stroke affected and unaffected siblings were recruited primarily 
using proband-initiated contact. All affected individuals had WHO-defined stroke confirmed by a 
study neurologist to be ischemic on the basis of brain imaging. Peripheral blood DNA samples were 
collected between October 2000 and December 2009.  
The Ischemic Stroke Genetics Study (ISGS): Ischemic Stroke Genetics Study (ISGS) was a 5-
center, prospective, case-control study of first-ever ischemic stroke cases.2 All affected individuals 
had WHO-defined stroke confirmed by a study neurologist to be ischemic on the basis of head CT or 
brain MRI. Peripheral blood DNA samples were collected between May 2003 and September 2008.  
Massachusetts General Hospital (MGH): Cases presenting with ischemic stroke and admitted to the 
Massachusetts General Hospital (MGH) Stroke Unit through the Emergency Department, or 
evaluated in the MGH Neurology outpatient clinics, as well as on the inpatient Medical and Vascular 
Surgical services from January 2003 to July 2008.3 Ischemic stroke was defined as either (1) a 
radiographically proven (head CT or MRI) infarct associated with the appropriate clinical stroke 
syndrome, or (2) a fixed neurological deficit persisting more than 24 hours, consistent with a 
vascular pattern of involvement and without radiographic evidence of demyelinating or other non-
vascular disease. All subjects were evaluated by a neurologist upon presentation and clinical and 
laboratory data were collected during the admission for qualifying ischemic stroke event.  All 
patients had acute brain imaging as well as ancillary diagnostic investigations: cervical and 
intracranial vessel imaging using CT or MR angiography (75%), cervical ultrasound (24%), 
echocardiography (86%), and Holter monitoring (16%).  
Milan Study: This study includes consecutive Italian patients referred to Besta Institute from 2000 to 
2009 with stroke and included in the Besta Cerebrovascular Diseases Registry (CEDIR).4 Ischemic 
stroke cases, first ever or recurrent, confirmed on brain imaging, were selected for this study. An 
experienced stroke neurologist assessed all cases. 
Wellcome Trust Case-Control Consortium 2 (WTCCC2): The WTCCC2 samples were genotyped 
as part of the WTCCC 2 ischemic stroke study. Stroke cases were recruited from three centers in the 
UK (St. George's Oxford and Edinburgh) and one center in Germany, University and Klinikum 
Großhadern, Ludwig-Maximilians-University, Munich.4  
WTCCC2-UK: The St George’s Stroke Study consecutively recruited ischemic stroke patients 
attending cerebrovascular services between 1995 and 2008 (n=1224). The Oxford Vascular Study 
recruited patients with acute ischemic stroke or transient ischemic attack (TIA) with evidence of 
infarction on brain imaging between 2002 and 2008 as part of a population-based study (n=896). The 
Edinburgh Stroke Study prospectively recruited consecutive stroke inpatients and outpatients 
between 2002 and 2005.  
WTCCC2-D: The Munich study recruited consecutively between 2002 and 2008, from a single 
Stroke Unit with a high rate of MR imaging (>80%) (n=1383). All subjects were over 18 years of 
age, of self-reported European ancestry and with a diagnosis of ischemic stroke classified according 
to TOAST by an experienced neurologist or stroke physician. All patients had brain imaging as well 
as ancillary diagnostic investigations where clinically relevant.  
 
 
STROKE SUBTYPE DEFINITIONS 
 
 
Stroke cases were subtyped based on their likely etiology using the TOAST criteria.5 Small vessel 
disease subtypes (SVD) are defined as those with a compatible history and imaging findings and in 
the absence of any thromboembolic sources as assessed by cerebral vascular imaging and 
electrocardiogram. Large artery atherosclerosis stroke was defined as clinical and brain imaging 
findings compatible with extracranial or intracranial cerebral artery occlusion or stenosis of at least 
50% on duplex or angiography in the absence of a potential cardiogenic embolic source. 
Cardioembolic stroke was assigned in those with a compatible clinical and imaging findings in the 




QUALITY CONTROL (QC) PROCEDURES 
 
Prior to imputation for all cohorts, individuals were removed if their inferred sex was discordant 
with the recorded sex or if they had more than 5% missing genotype data. Autosomal single 
nucleotide polymorphisms (SNPs) were excluded if the minor allele frequency was <1%, there was 
>5% missing data, or Hardy Weinberg p<1x10-6. Centre-specific checks for relatedness, duplicate 
samples and population stratification were performed. Additional quality control procedures were 
applied in which related individuals including first cousins were removed (relatedness pi-hat >/= 
0.125) and principal components analysis (PCA) was performed, incorporating genotype data from 
Phase 3 HapMap populations (CEU, CHB/JPT, YRI) in order to identify and remove non-European 
ancestry individuals (Figure I).  
 
Imputation was performed in all centers using IMPUTE26 and HapMap3 and 1000 Genomes Project 
Phase pilot (June 2010). Imputed genotype dosage data was converted to hard-call using a strict 
level of confidence (observed dosage variance to expected binomial variance of r2 >0.95) in PLINK 
(http://pngu.mgh.harvard.edu/~purcell/plink/). Strict quality control procedures were then applied on 
a per center basis; SNPs that were either rare (minor allele frequency <0.01) or missing in more than 
1% of genotypes were discarded. Following QC, there were 472591 consensus autosomal SNPs 
from the merged genotyped data remaining for heritability analysis.  
 
As there were multiple genotyping platforms, imputed data maximized the number of consensus 
SNPs and therefore genomic coverage retained for heritability analysis. Although the restricted 
maximum likelihood model within the Genomic Complex Trait Analysis (GCTA) Tool is adjusted 
for incomplete linkage disequilibrium (LD) with causal variants, it assumes that the LD between 
SNPs and causal variants is similar to the LD between the SNPs used. Therefore there is a reduction 
in standard error when more SNPs are used7. Genotypes were converted to hard call retaining only 
SNPs imputed to the highest quality in order to minimize propagating genotyping platform bias6,8. 
 
 
RATIONAL FOR WHITE MATTER VOLUME ADJUSTMENTS 
 
The distribution of WMHV was positively skewed and therefore values were natural log-transformed 
after addition of half the minimum value (10mm3). The mean and standard deviation of WMHV and 
TICV or ICA amongst the different groups are shown in Table I. One-way ANOVA demonstrated 
significant differences transformed WMHV amongst the groups (F=95.5 df=8, P<0.001). WMHV 
increases with age as seen in Figure III. In a linear regression model age was a significant predictor 
of transformed WMHV (B=0.062, SE=0.003, p<0.001). Residuals from these models were placed in 
regression model again with age, which revealed that age was adequately controlled for (B=0.00 
SE=0.003, p=1.00). 
 
Chi-Square statistics were used to compare observed and expected frequencies of cardiovascular risk 
factors, amongst different groups and revealed significant differences for all risk factors except sex. 
Due to this heterogeneity, standardized WMH residuals were derived on a per group basis prior to 




4) HERITABILITY BY CHROMOSOME 
 
Partitioning heritability by chromosome revealed the highest variance was attributable to 
chromosomes 6 and 12 (HSNP =0.046, se=0.026, p=0.029 and HSNP =0.042, se=0.022, p=0.014, 
respectively) (Table IV) but also significant associations were found with chromosome 11, 14 and 
17. The latter accounted for 3.2% of the SNP heritability (p=0.014) and is relevant because to date 
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